Frederic Bouvier Joins Chime Biologics as Vice President of Business Development, Overseas (Europe) and Head of Global Strategy & Partnerships

  • Chime Biologics strengthens global reach with new Europe-based leader
  • Fast-track European expansion and bridge China-global innovation
  • Leveraging our extensive experience in biosimilar development and commercial-scale manufacturing to deliver high-quality and affordable therapies that expand patient access worldwide

September 1, 2025, Wuhan, China – Chime Biologics, a leading global CDMO that enables its partners’ success in biologics, today announced the appointment of Frederic Bouvier, Ph.D., as Vice President of Business Development, Overseas (Europe) and Head of Global Strategy & Partnerships. Dr. Bouvier will be based in Switzerland.

Dr. Bouvier brings more than two decades of experience in biologics, biosimilars, and advanced therapies, seamlessly integrating rigorous scientific insight with strategic and commercial acumen. His career spans the entire biologics value chain—from early-stage cell-line engineering and process development through commercial launch and lifecycle management—across modalities including monoclonal antibodies, ADCs, and vaccines. Prior to joining Chime Biologics, he held senior leadership roles at MiGenTra, Fresenius Kabi, and Sanofi. Dr. Bouvier earned his Ph.D. in Molecular Biology from Université Louis Pasteur.

Dr. Bouvier’s track record of steering both Big Pharma and specialized CDMOs gives us immediate strategic leverage across Europe and beyond. By tightly coupling China’s end-to-end biologics innovation with the global biopharmaceutical community, he will compress development timelines and expand patient access to new medicines.

“Dr. Bouvier’s arrival reaffirms our relentless pursuit of world-class talent,” said Dr. Jimmy Wei, President of Chime Biologics. “His dual command of science and strategy will translate excellence into growth, deepen our European footprint, strengthen global partnerships, and accelerate the transformative value we deliver to partners and patients worldwide.”

About Chime Biologics

Chime Biologics is a leading global CDMO, focused on ensuring our customers' success in delivering innovative biologic medicines to patients across the world. Chime Biologics can support customers end to end, from pre-clinical support and cell line development through to clinical and commercial manufacturing of drug substance and drug product. Employing our innovative and state-of-the-art development and manufacturing capabilities and proven success in supporting our clients with their clinical and commercial authorizations across the globe, Chime Biologics is a true end-to-end solution provider for the biologics industry. With over 500 skilled employees, we share a common goal to make cutting-edge biomedicines affordable and accessible to patients worldwide, fulfilling our commitment to improving human health globally. For more information, please visit www.chimebiologics.com.